Retrospective Evaluation of Oral Glucose Tolerance Test in Young Patients with Transfusion-Dependent Beta-Thalassemia

Maria Dritsa1, Marina Economou1, Vasilios Perifanis2

  • 11st Paediatric Department, School of Medicine, Hippokratio General Hospital, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Acta Haematologica
|March 2, 2022
PubMed

Insights

Yearly oral glucose tolerance tests (OGTT) for thalassemia major (TM) patients in their second decade may not be necessary. New criteria could reduce testing by 46%, ensuring timely detection of glucose intolerance without unnecessary tests.

Area of Science:

  • Endocrinology
  • Hematology
  • Pediatrics

Background:

  • Current guidelines recommend annual oral glucose tolerance tests (OGTT) for thalassemia major (TM) patients starting at age 10.
  • Glucose metabolism evaluation is crucial for managing TM complications.

Purpose of the Study:

  • To retrospectively evaluate OGTTs in pediatric TM patients over a decade.
  • To assess the necessity of yearly OGTTs during the second decade of life for TM patients.

Main Methods:

  • Analysis of 170 OGTT tests from 39 TM patients (ages 10-19).
  • Identification of patients with impaired glucose tolerance (IGT) or diabetes mellitus.
  • Development of selective criteria for OGTT performance.

Main Results:

  • Only 10% of tests showed impaired glucose tolerance (IGT), and 1.18% indicated diabetes mellitus.
  • No significant differences in demographics, ferritin levels, or transfusion volume were found between patients with normal and abnormal glucose metabolism.
  • Proposed criteria could reduce the number of OGTTs by 46.47% (from 170 to 91).

Conclusions:

  • A small percentage of young, transfusion-dependent TM patients develop abnormal glucose metabolism in their second decade.
  • Implementing specific selection criteria can significantly decrease the number of performed OGTTs.
  • This approach allows for timely detection and intervention while reducing resource utilization.
Abstract

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
25.3K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.1K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
364
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
304
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
327
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
288